Approval · Notice of Compliance 19157 · 2017
LUCENTIS: Notice of Compliance 19157
Issued April 12, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19157
- Date
- April 12, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUCENTIS | Not yet assigned | — |
Medicinal ingredients
- RANIBIZUMAB 10 MG per ML
- RANIBIZUMAB 10 MG per VIAL